Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial
European Journal of Cancer · 2026-11 · 248 · 117037
DOI: 10.1016/j.ejca.2026.117037 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Michael Masetti und 24 weiteren Autor:innen. Beteiligte Einrichtung: TUM University Hospital rechts der Isar, Department of Medicine III, Munich, Germany. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Nivolumab. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Krebsforschungszentrum.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- TUM University Hospital rechts der Isar, Department of Medicine III, Munich, Germany.
- The Frankfurt Institute of Clinical Cancer Research and Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt, Germany.
- Charité - Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
- University Hospital Marburg, Department of Internal Medicine, Marburg, Germany.
- Hematology-Oncology Practice Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Hamburg, Germany.
- Oncology Ravensburg, Ravensburg, Germany.
Förderung
- Deutsches Krebsforschungszentrum
Zitieren
APA
Masetti, M., Nieto, A., Lorenzen, S., Goetze, T. O., Thuss-Patience, P. C., Riera-Knorrenschild, J., Goekkurt, E., Dechow, T. N., Ettrich, T. J., Hofheinz, R. D., Luley, K. B., Pink, D., Lindig, U., Folprecht, G., Schuch, G., Bitzer, M., Heinemann, V., Angermeier, S., Bolling, C., …, & Tintelnot, J. (2026). Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial. European Journal of Cancer, 248, 117037. https://doi.org/10.1016/j.ejca.2026.117037
Vancouver
Masetti M, Nieto A, Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, et al. Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial. European Journal of Cancer. 2026;248:117037. doi:10.1016/j.ejca.2026.117037
BibTeX
@article{Masetti2026,
author = {Masetti, Michael and Nieto, Alexander and Lorenzen, Sylvie and Goetze, Thorsten Oliver and Thuss-Patience, Peter C and Riera-Knorrenschild, Jorge and Goekkurt, Eray and Dechow, Tobias Nicolaas and Ettrich, Thomas Jens and Hofheinz, Ralf Dieter and Luley, Kim Barbara and Pink, Daniel and Lindig, Udo and Folprecht, Gunnar and Schuch, Gunter and Bitzer, Michael and Heinemann, Volker and Angermeier, Stefan and Bolling, Claus and Loose, Maria and Junge, Sabine and Pauligk, Claudia and Al-Batran, Salah-Eddin and Stein, Alexander and Tintelnot, Joseph},
title = {Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117037},
doi = {10.1016/j.ejca.2026.117037}
}
EUVIMED